RecruitingNCT07269873
Safety of a long-acting naltrexone implant with or without bupropion
About this title
Read the official source — NCT07269873Medication studyAges 18–65United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- MiamiSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 16, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 30
- Sponsor
- BioCorRx Pharmaceuticals Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT07269873
- Official title
Show the full official title
A Sequential Dose Cohort Pharmacokinetic and Safety Study of Implantable Long-Acting Naltrexone Subcutaneous Pellets With or Without Bupropion Compared to Naltrexone IM Injection (Vivitrol®) in Healthy Normal Volunteers
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Miami
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is BioCorRx Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including BICX104 naltrexone implantable pellet, Bupropion 150 mg XL and Naltrexone (depot).
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
